Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.
Affiliation
Wolfson Molecular Imaging Centre, The University of Manchester, Manchester, UKIssue Date
2015-08-26
Metadata
Show full item recordAbstract
Antiangiogenic therapy of vestibular schwannoma (VS) in type 2 neurofibromatosis can produce tumor shrinkage with response rates of 40%-60%. This study examines the predictive value of parameter-derived MRI in this setting.Citation
Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. 2015: Neuro-oncologyJournal
Neuro-oncologyDOI
10.1093/neuonc/nov168PubMed ID
26311690Type
ArticleLanguage
enISSN
1523-5866ae974a485f413a2113503eed53cd6c53
10.1093/neuonc/nov168
Scopus Count
Collections
Related articles
- Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
- Authors: Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA
- Issue date: 2019 Dec 10
- Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
- Authors: Hochart A, Gaillard V, Baroncini M, André N, Vannier JP, Vinchon M, Dubrulle F, Lejeune JP, Vincent C, Nève V, Sudour Bonnange H, Bonne NX, Leblond P
- Issue date: 2015 Sep
- The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
- Authors: Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF
- Issue date: 2015 Dec
- Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
- Authors: Ouerdani A, Goutagny S, Kalamarides M, Trocóniz IF, Ribba B
- Issue date: 2016 Jun
- Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
- Authors: Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR
- Issue date: 2016 May 10